Telitacicept to help keep ANCA vasculitis in remission
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), confirmed by 2022 ACR/EULAR criteria
- Your disease is currently in complete remission (BVAS 0) and your daily prednisone is 10 mg or less
- You were ANCA-positive at diagnosis or became ANCA-positive during your disease
- You likely do not have certain exclusions like major organ problems, active serious infections, or certain liver/heart/kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
This study tests a medicine called telitacicept for children with IgA nephropathy or IgA vasculitis nephritis, two kidney diseases that cause protein in the urine. The goal is to see if the medicine can reduce protein loss and help protect the kidneys.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.